The Public Pays Twice: How $187 Billion in Federal Grants Backs 99 Percent of Novel Drug Approvals

When the federal government funds a new interstate highway, the public drives on it without paying a private toll operator for the asphalt. The state absorbs the construction cost, and the taxpayer reaps the direct benefit of the infrastructure.[4]

The pharmaceutical market operates on the exact opposite principle. When the National Institutes of Health funds the foundational science for a blockbuster drug, the public pays a private monopoly to access the resulting cure.[2][4]

The pharmaceutical industry justifies the highest drug prices in the developed world by pointing to the astronomical costs of research and development. They argue that monopoly pricing is the necessary reward for absorbing the massive financial risks of drug discovery.[5]

That foundational argument is structurally false. A comprehensive analysis of federal funding reveals that the public sector, not private industry, underwrites the vast majority of the early scientific risk.[4]

Between 2010 and 2019, the National Institutes of Health distributed $187 billion in federal grants that directly contributed to foundational research. That public money did not just fund abstract academic exercises; it built the biochemical architecture for modern medicine.[2]

The Myth of Private Discovery

According to research published by Bentley University and the Institute for New Economic Thinking, that $187 billion in taxpayer funding was associated with published research for 99.4 percent of all novel drugs approved by the FDA during that decade.[1][2]

Out of 356 new molecular entities approved by regulators, 354 were directly linked to NIH-funded science. The public sector is not merely a participant in drug discovery; it is the indispensable engine that drives it.[2]

To understand why this matters, one must look at how a drug actually moves from a concept to a pharmacy shelf. The process is divided into basic research, translational science, and clinical trials.[4]

Basic research involves identifying a biological target, such as a specific protein involved in tumor growth. This is the most unpredictable and failure-prone stage of the scientific process, often taking decades of painstaking laboratory work.[1]

Private pharmaceutical companies rarely fund this foundational stage. The financial risk is simply too high, and the timeline to a patentable product is too long to satisfy quarterly earnings expectations.[5]

Socializing the Scientific Risk

Instead, the NIH steps in to fill the void. Federal grants fund the university researchers and government scientists who map the human genome, identify disease pathways, and discover the underlying mechanisms of action.

The Bentley University study found that 83 percent of the $187 billion in NIH funding went toward basic research on drug targets. Only 17 percent involved applied research on the drugs themselves.[1]

The discoveries that are supported by NIH funds are generally targets, mechanisms, and platforms, the researchers noted. In nearly all cases, the government paid for the biology and industry paid for the molecule.[1]

Consider the development of modern cancer immunotherapies, which unleash the body's own immune system to attack tumors. The foundational work on the PD-1 protein, which makes these blockbusters possible, was funded by NIH grants starting in the late 1970s.

Decades of publicly funded academic research at institutions like the University of Texas MD Anderson Cancer Center mapped the complex biology of immune checkpoints. The private sector only stepped in once the mechanism was proven viable.

Today, drugs targeting the PD-1 pathway generate tens of billions of dollars in annual revenue for private pharmaceutical companies. The taxpayers who funded the initial discovery receive no direct royalty on those sales.

Once the basic science is established and the biological target is de-risked, private industry acquires the intellectual property. They patent the specific molecule that interacts with the publicly discovered target.[3]

The Cost of Commercialization

The pharmaceutical industry vigorously defends its pricing model by pointing to the later stages of development. Industry groups note that aggregate research and development expenditures by top companies exceed $120 billion annually.[5]

That figure is real, but it represents a fundamentally different kind of investment. Private research spending is overwhelmingly concentrated in Phase II and Phase III clinical trials, which test safety and efficacy in human patients.[5]

Clinical trials are undeniably expensive, often costing hundreds of millions of dollars per drug. Running multi-center, double-blind studies requires massive logistical coordination, patient recruitment, and strict regulatory compliance.[4]

A 2022 analysis of investigational therapies found that for certain oncology drugs, private sector investment during the clinical phase exceeded $5 billion per therapy. Industry advocates argue this massive late-stage expenditure is what actually brings a drug across the regulatory finish line.[5]

However, funding a clinical trial is not the same as discovering a drug. The private sector is paying for the commercialization and regulatory clearance of a scientific breakthrough that taxpayers already financed.[4]

By the time a pharmaceutical company commits to a Phase III trial, the foundational scientific risk has largely been eliminated. The company is taking a regulatory and commercial risk, not a basic discovery risk.[2]

This division of labor creates a profound economic imbalance. The public pays the first time through taxation, funding the $187 billion in NIH grants that make the underlying science possible.[2]

The Double Payment Problem

The public then pays a second time at the pharmacy counter. Because the private company holds the patent on the final molecule, it is granted a period of market exclusivity by the federal government.[3]

During this exclusivity period, the company can charge whatever the market will bear. In the United States, which lacks the centralized price controls of other developed nations, this results in astronomical retail costs.[4]

The Bayh-Dole Act of 1980 was designed to encourage the commercialization of federally funded research by allowing universities to patent and license their discoveries to private companies.

While the law succeeded in bringing more drugs to market, it failed to protect the taxpayers who funded the initial research. The legislation includes march-in rights that theoretically allow the government to intervene if a drug is not made available on reasonable terms.[3]

Despite decades of exorbitant drug prices, the federal government has never once exercised its march-in rights. The pharmaceutical industry has successfully lobbied to keep this consumer protection mechanism entirely dormant.[4]

Re-evaluating the Risk Premium

The industry's central lobbying argument relies on the threat of diminished innovation. They claim that any attempt to regulate prices will immediately halt the development of new life-saving therapies.[5]

The NIH funding data demolishes this threat. If 99.4 percent of novel approvals are rooted in public science, then the true engine of innovation is the federal budget, not the profit margins of private monopolies.[2]

Private capital is certainly necessary to fund the expensive clinical trials required for FDA approval. But that capital is replaceable, and it does not justify granting a permanent, unmitigated monopoly on the resulting medicine.[4]

If pharmaceutical companies were forced to accept lower prices, they might reduce their spending on stock buybacks and marketing. They would not, however, stop commercializing the de-risked scientific breakthroughs handed to them by the NIH.[4]

The current system represents a massive transfer of wealth from the public to the private sector. Taxpayers socialize the immense risks of basic scientific discovery, while private corporations privatize the financial rewards.[2]

A Return on Public Investment

Acknowledging the $187 billion public contribution changes the fundamental nature of the drug pricing debate. It shifts the conversation from a question of market interference to a question of return on public investment.[4]

When a patient cannot afford a life-saving medication, they are not just being priced out of a private market. They are being denied access to a scientific breakthrough that their own tax dollars helped create.[4]

The pharmaceutical industry did not invent the modern medical miracle on its own. It built its empire on a foundation of public science, and it is time the public demanded a fair return on its investment.[4]